Drug Monograph
Sinemet (Carbidopa-Levodopa)
carbidopa and levodopa
Pharmacokinetic Profile
Half-Life (Levodopa)
~1.5 h (with carbidopa)
Half-Life (Carbidopa)
1.6–2 h
Metabolism
Peripheral AADC & COMT
Protein Binding
LD: 10–30%; CD: ~36%
Bioavailability (CD)
~99% (from Sinemet)
Volume of Distribution
~65% body weight (LD)
Clinical Information
Drug Class
Dopamine precursor + DDC inhibitor
Available Doses (IR)
10/100, 25/100, 25/250 mg
Available Doses (CR)
25/100, 50/200 mg
Route
Oral
Renal Adjustment
Use with caution; titrate to effect
Hepatic Adjustment
Caution; limited data
Pregnancy
Category C (animal harm)
Lactation
LD detected in milk; may inhibit lactation
Schedule / Legal Status
Prescription only (not scheduled)
Generic Available
Yes
Therapeutic Index
Narrow (dose-dependent dyskinesias)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Parkinson’s disease | Adults | Monotherapy or adjunctive | FDA Approved |
| Post-encephalitic parkinsonism | Adults | Monotherapy or adjunctive | FDA Approved |
| Symptomatic parkinsonism (carbon monoxide intoxication) | Adults | Monotherapy or adjunctive | FDA Approved |
| Symptomatic parkinsonism (manganese intoxication) | Adults | Monotherapy or adjunctive | FDA Approved |
Carbidopa-levodopa remains the most effective pharmacotherapy for the motor symptoms of Parkinson’s disease and is considered first-line treatment by major neurological societies. The combination is the cornerstone of dopaminergic replacement, with carbidopa serving to prevent premature peripheral conversion of levodopa to dopamine, thereby allowing a greater fraction to reach the central nervous system.
Off-Label Uses
Restless legs syndrome (RLS): Intermittent use for symptom relief when dopamine agonists are not tolerated. Evidence quality: Moderate.
Dopa-responsive dystonia (Segawa syndrome): Very low doses provide dramatic and sustained benefit. Evidence quality: High (diagnostic hallmark of the condition).
Dosing
Immediate-Release Tablets
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Parkinson’s disease — levodopa-naïve, mild symptoms | 25/100 mg TID | 25/100–25/250 mg TID–QID | 200/800 mg/day | Increase levodopa by 100 mg/day every 1–2 days Ensure carbidopa ≥70 mg/day |
| Parkinson’s disease — levodopa-naïve, prominent tremor or stiffness | 25/100 mg TID | 25/250 mg TID–QID | 200/800 mg/day | May start 10/100 mg TID–QID if more gradual titration preferred Faster titration may be needed for more disabling symptoms |
| Conversion from levodopa alone — total LD <1500 mg/day | 25/100 mg TID–QID | Titrate to prior response level | 200/800 mg/day | Discontinue levodopa ≥12 h before switching Starting LD dose ~25% of previous daily LD |
| Conversion from levodopa alone — total LD ≥1500 mg/day | 25/250 mg TID–QID | Titrate to prior response level | 200/800 mg/day | Discontinue levodopa ≥12 h before switching Starting LD dose ~25% of previous daily LD |
| Motor fluctuations — wearing-off pattern | Maintain current total daily dose | Fractionate into more frequent, smaller doses | 200/800 mg/day | Shorten inter-dose interval to Q3–4h Consider switch to CR or ER capsule if frequent dosing inconvenient |
Controlled-Release (CR) Tablets
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Parkinson’s disease — levodopa-naïve | 50/200 mg BID | 50/200 mg BID–QID | Levodopa 1600 mg/day | Allow ≥6 h between initial doses CR bioavailability ~70% of IR; dose adjustment needed |
| Conversion from IR — managing motor fluctuations | Total daily LD +10–30% of prior IR LD | Titrate Q3d to response | Levodopa 1600 mg/day | CR releases over 4–6 h Swallow whole; do not crush or chew |
Extended-Release (ER) Capsules (Rytary / CREXONT)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Parkinson’s disease — levodopa-naïve (Rytary) | 23.75/95 mg TID | 36.25/145–97.5/390 mg TID–5x daily | 612.5/2450 mg/day | On day 4 may increase to 36.25/145 mg TID ER capsule doses NOT interchangeable with IR doses |
| Advanced PD with motor fluctuations (CREXONT) | Convert from IR per tables | Titrate Q1–3d to response | 525/2100 mg/day | Take with or without food; do not crush High-fat meal delays Tmax by ~2 h |
Elderly Patients
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Age ≥75 years — any formulation | 25/100 mg BID–TID (IR) | Titrate slowly to response | Same as adults; often lower doses sufficient | AUC of levodopa increased ~55% vs younger adults Higher sensitivity to hallucinations and orthostatic hypotension |
Clinical Pearl: Carbidopa Threshold
A minimum of 70–100 mg/day of carbidopa is needed to saturate peripheral dopa decarboxylase. If carbidopa intake falls below this threshold (e.g., using 10/100 tablets at low frequency), patients may experience more nausea and reduced levodopa bioavailability. Supplemental carbidopa (Lodosyn 25 mg) can be added if needed without changing levodopa dose.
Do Not Abruptly Discontinue
Sudden withdrawal of carbidopa-levodopa can precipitate a neuroleptic malignant syndrome–like condition with hyperpyrexia, muscular rigidity, and altered consciousness. Always taper gradually.
Pharmacology
Mechanism of Action
Levodopa is an amino acid precursor that crosses the blood–brain barrier and undergoes decarboxylation to dopamine within the nigrostriatal pathway, replenishing the depleted dopamine stores that underlie Parkinson’s motor symptoms. Without a peripheral decarboxylase inhibitor, the majority of an oral levodopa dose is converted to dopamine in the gut and circulation before reaching the brain, producing nausea, vomiting, and cardiovascular side effects while wasting the active drug. Carbidopa is a competitive inhibitor of aromatic L-amino acid decarboxylase (AADC, also called dopa decarboxylase) that does not penetrate the blood–brain barrier. By blocking peripheral AADC, carbidopa reduces the required levodopa dose by approximately 75%, extends the plasma half-life from about 50 minutes to roughly 1.5 hours, and substantially reduces peripheral dopaminergic adverse effects.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Levodopa Tmax ~0.5–2 h (IR); absorbed in proximal small intestine via large neutral amino acid transporter | High-protein meals compete for absorption; take 30–60 min before meals for optimal response in fluctuating patients |
| Distribution | Levodopa Vd ~65% body weight; protein binding 10–30% (LD), ~36% (CD); <1% of absorbed LD crosses BBB | Wide tissue distribution (pancreas, liver, GI, salivary glands); low BBB penetration makes peripheral AADC inhibition critical |
| Metabolism | Primary: decarboxylation by AADC (inhibited by carbidopa); secondary: COMT to 3-O-methyldopa (3-OMD, t½ ~13 h); minor: MAO | 3-OMD accumulates during chronic therapy; COMT inhibitors (entacapone) extend levodopa effect by blocking this pathway |
| Elimination | t½ levodopa ~1.5 h (with CD); t½ carbidopa 1.6–2 h; metabolites excreted renally; minimal levodopa accumulation | Short half-life drives pulsatile dopamine stimulation; frequent dosing or ER formulations needed to manage motor fluctuations |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | ~20% | Peripheral dopaminergic effect; improves with slow titration and dosing with food; far less than with levodopa alone |
| Dyskinesia / involuntary movements | 12–17% | Dose-dependent; appears sooner with combination than levodopa alone; blepharospasm may be an early sign of excess dosing |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness / light-headedness | ~5–8% | Often related to orthostatic hypotension; advise slow positional changes |
| Orthostatic hypotension | ~2–5% | More frequent with concurrent antihypertensives; check standing blood pressure during titration |
| Somnolence / excessive daytime sleepiness | ~2–5% | Warn about driving; sudden sleep attacks possible without warning signs |
| Insomnia | ~3–6% | Avoid late-evening dosing when possible |
| Hallucinations | ~3–5% | Visual hallucinations more common; elderly patients at higher risk; dose reduction or pimavanserin may help |
| Confusion / agitation | ~2–4% | Cognitive adverse effects rise with advancing disease and polypharmacy |
| Vomiting | ~2–5% | Usually transient; domperidone (where available) may help; avoid metoclopramide |
| Depression | ~2–3% | Monitor for suicidal ideation; PD itself carries elevated depression risk |
| Headache | ~2–5% | Usually self-limiting; more commonly reported with ER capsule formulations |
| Abnormal dreams / nightmares | ~2–4% | May precede overt hallucinations; reassess dopaminergic load if vivid |
| Dark discoloration of urine / sweat | Common | Benign levodopa metabolite effect; warn patients to expect red-brown-black discoloration of body fluids |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Neuroleptic malignant syndrome–like reaction | Rare | Hours to days after abrupt dose reduction or withdrawal | Resume dopaminergic therapy; supportive ICU care; dantrolene or bromocriptine |
| Impulse control disorders (pathological gambling, hypersexuality, compulsive spending/eating) | ~6–14% (class effect) | Weeks to months after initiation or dose increase | Screen at every visit; reduce dopaminergic load; specialist referral if severe |
| Psychosis (delusions, paranoid ideation) | ~3–5% | Variable; more frequent with advanced PD and higher doses | Rule out infection/metabolic cause; reduce polypharmacy; consider pimavanserin or quetiapine |
| Vitamin B6 deficiency–associated seizures | Rare (14 FDA-identified cases) | 23–132 months; all cases at LD >1000 mg/day | Administer vitamin B6; anti-seizure medications often ineffective for these seizures (FDA 2026) |
| Sudden onset of sleep (“sleep attacks”) | Rare, unpredictable | Any time; reported up to 1 year after initiation | Discontinue driving; reassess need for all sedating medications; consider dose reduction |
| Upper GI hemorrhage | Rare | Variable | Use with caution in patients with peptic ulcer history; GI referral if symptoms develop |
| Cardiac arrhythmias | Rare | Early titration period in patients with pre-existing cardiac disease | ECG monitoring during initial titration in at-risk patients; intensive cardiac care availability |
| Melanoma (increased risk in PD patients) | 2–6× higher risk (unclear if drug- or disease-related) | Chronic use; ongoing risk | Periodic dermatological surveillance recommended for all PD patients on levodopa |
Discontinuation
Discontinuation Rates
Adults (5-year CR First Study)
<10% drug-related withdrawals
Top reasons: Nervous/psychiatric complaints, nausea, dyskinesia
ER Capsule (Early PD Trials)
~7–10% vs ~5% placebo
Top reasons: Nausea, dizziness, insomnia, dyskinesia
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Neuropsychiatric symptoms | ~3–5% | Hallucinations, confusion, depression; more common in elderly and advanced disease |
| Dyskinesia | ~2–3% | Involuntary movements intolerable despite dose reduction |
| Gastrointestinal intolerance | ~1–3% | Nausea and vomiting unresponsive to dose adjustment or timing changes |
Managing Dyskinesia
Dyskinesia is the most clinically significant dose-limiting adverse effect. Strategies include reducing individual levodopa doses, fractionating total daily dose into more frequent smaller administrations, adding amantadine (an NMDA antagonist with anti-dyskinetic properties), or switching to an extended-release formulation to reduce pulsatile dopamine delivery.
Drug Interactions
Levodopa is not metabolized by cytochrome P450 enzymes. Its primary metabolic pathways involve decarboxylation (blocked by carbidopa), COMT-mediated O-methylation, and minor MAO oxidation. Interactions are therefore predominantly pharmacodynamic or related to absorption rather than classic CYP-mediated.
Major
Nonselective MAO Inhibitors (phenelzine, tranylcypromine, isocarboxazid)
MechanismInhibition of both MAO-A and MAO-B prevents dopamine breakdown
EffectHypertensive crisis; risk of serotonin-like syndrome
ManagementAbsolutely contraindicated; MAOI must be stopped ≥14 days before starting C/L
FDA PI
Major
Dopamine D2 Antagonists (haloperidol, risperidone, chlorpromazine, metoclopramide)
MechanismDirect blockade of postsynaptic dopamine receptors in the basal ganglia
EffectLoss of therapeutic effect; worsening parkinsonism; drug-induced parkinsonism
ManagementAvoid if possible; use quetiapine, clozapine, or pimavanserin for PD psychosis instead; use domperidone for nausea (does not cross BBB)
FDA PI
Moderate
Selegiline / Rasagiline (MAO-B Inhibitors)
MechanismSelective MAO-B inhibition reduces dopamine breakdown in the brain
EffectPotentiation of levodopa effects; severe orthostatic hypotension reported with selegiline
ManagementCombination is standard of care at recommended doses; monitor BP; may need levodopa dose reduction
FDA PI
Moderate
Iron Salts / Iron-Containing Multivitamins
MechanismIron chelates with levodopa and carbidopa in the GI tract
EffectReduced absorption and bioavailability of both drugs
ManagementSeparate administration by ≥2 hours; monitor for loss of motor response
FDA PI
Moderate
Antihypertensive Agents
MechanismAdditive blood pressure reduction via peripheral dopaminergic vasodilation
EffectSymptomatic postural hypotension
ManagementAdjust antihypertensive dosing when starting C/L; monitor standing BP during titration
FDA PI
Moderate
Tricyclic Antidepressants
MechanismMultiple mechanisms including norepinephrine reuptake inhibition
EffectRare reports of hypertension and dyskinesia
ManagementMonitor blood pressure and motor symptoms; adjust doses as clinically indicated
FDA PI
Moderate
Isoniazid
MechanismUnknown; may inhibit dopa decarboxylase
EffectReduced therapeutic effect of levodopa
ManagementMonitor motor function; may need levodopa dose increase; also depletes B6, compounding new FDA B6 warning
FDA PI / Lexicomp
Minor
High-Protein Meals
MechanismLarge neutral amino acids compete with levodopa for intestinal absorption and BBB transport
EffectReduced or delayed motor response to individual doses
ManagementDistribute protein evenly or shift to evening; take C/L 30–60 min before meals for fluctuating patients
FDA PIMonitoring
-
Vitamin B6 Level
Baseline, then periodically
Routine New FDA requirement (March 2026). Evaluate before starting therapy and at intervals during treatment. Supplement if deficient. Higher risk at LD >1000 mg/day. -
Motor Response
Each visit
Routine Assess for wearing-off, on-off fluctuations, peak-dose dyskinesias, and early morning dystonia. Use a motor diary when fluctuations emerge. -
Blood Pressure
Baseline, each titration visit
Routine Measure lying and standing; orthostatic hypotension is common, especially when co-prescribed with antihypertensives or MAO-B inhibitors. -
Neuropsychiatric Status
Each visit
Routine Screen for hallucinations, psychotic symptoms, depression, suicidal ideation, and impulse control disorders (gambling, hypersexuality, compulsive behaviors). -
Hepatic Function
Baseline, then periodically
Routine FDA PI recommends periodic hepatic, hematopoietic, cardiovascular, and renal evaluation during extended therapy. ALT/AST elevations possible. -
CBC
Baseline, then periodically
Routine Positive Coombs test and decreased hemoglobin/hematocrit have been reported. Anemia may also result from B6 deficiency. -
Intraocular Pressure
Periodically if wide-angle glaucoma
Trigger-Based Patients with chronic wide-angle glaucoma may be treated cautiously provided IOP is well-controlled and monitored during therapy. -
Skin Examination
Annually (or per dermatology schedule)
Routine PD patients have a 2–6× higher melanoma risk; periodic skin examination by a qualified professional is recommended regardless of drug use. -
Homocysteine Level
Consider at baseline and periodically
Trigger-Based Levodopa metabolism raises homocysteine via COMT pathway. Elevated levels may contribute to cardiovascular risk and peripheral neuropathy.
Contraindications & Cautions
Absolute Contraindications
- Concurrent use of nonselective MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid): Must discontinue for ≥14 days before starting carbidopa-levodopa. Risk of hypertensive crisis.
- Narrow-angle glaucoma: Dopamine-mediated mydriasis may precipitate angle closure.
- Known hypersensitivity to carbidopa, levodopa, or any excipient.
Relative Contraindications (Specialist Input Recommended)
- Active psychotic disorder: Levodopa may exacerbate psychosis; if PD treatment is essential, coordinate with psychiatry and consider pimavanserin or clozapine co-prescription.
- Active peptic ulcer disease: Levodopa may increase risk of upper GI hemorrhage; optimize ulcer treatment before initiating.
- History of melanoma or suspicious skin lesions: Epidemiological association between PD and melanoma; requires careful risk-benefit discussion and dermatological clearance.
Use with Caution
- Severe cardiovascular disease: Cardiac monitoring recommended during initial titration, particularly in patients with arrhythmia or recent myocardial infarction.
- Severe pulmonary disease / bronchial asthma
- Renal or hepatic impairment: Limited data; titrate cautiously to response.
- Endocrine disorders
- Chronic wide-angle glaucoma: Acceptable if IOP well-controlled and monitored (unlike narrow-angle, which is absolute).
- Elderly patients (≥75 years): Increased levodopa exposure (~55% higher AUC) and greater sensitivity to hallucinations and orthostatic hypotension.
FDA Required Warning (March 2026)
Vitamin B6 Deficiency and Seizures
Carbidopa-levodopa can deplete vitamin B6 through two mechanisms: metabolic consumption during levodopa-to-dopamine conversion, and direct binding of carbidopa to the active form of B6 (pyridoxal phosphate). The FDA identified 14 cases of B6-deficiency seizures, all at levodopa doses above 1000 mg/day. Seizures were refractory to conventional anti-seizure medications but resolved with vitamin B6 supplementation. Clinicians must evaluate B6 levels at baseline, periodically during treatment, and when symptoms of deficiency appear.
Patient Counselling
Purpose of Therapy
Carbidopa-levodopa replaces the dopamine that the brain can no longer produce in sufficient amounts because of Parkinson’s disease. It is the most effective medication for controlling the motor symptoms of PD, including tremor, stiffness, and slowness of movement. The carbidopa component prevents the levodopa from breaking down before it reaches the brain, reducing nausea and allowing a lower effective dose.
How to Take
Take the medication at regularly spaced intervals as prescribed. The immediate-release tablet works within about 30 minutes. Do not crush or chew controlled-release or extended-release formulations. Spacing doses evenly throughout waking hours helps maintain smooth symptom control. If motor fluctuations (wearing-off) develop, keep a diary and discuss timing adjustments with the prescriber.
Nausea & Vomiting
Tell patient
Nausea is common at the start and usually improves with continued use. Taking the medication with a small non-protein snack (crackers, toast) can help. Avoid taking with high-protein meals, as protein competes with levodopa absorption.
Call prescriber
If nausea is severe, persistent, or causes vomiting that prevents medication adherence.
Dizziness & Light-Headedness
Tell patient
Blood pressure may drop when standing quickly. Rise slowly from sitting or lying positions, especially in the morning or after meals. Stay hydrated.
Call prescriber
If fainting occurs, if dizziness is severe or does not improve with positional precautions, or if you experience chest pain or palpitations.
Drowsiness & Sleep Attacks
Tell patient
This medication can cause excessive sleepiness and, rarely, sudden onset of sleep without warning. Do not drive or operate heavy machinery until you know how the medication affects you. This risk can appear months after starting treatment.
Call prescriber
If you fall asleep suddenly during activities, experience excessive daytime sleepiness, or have a near-miss while driving.
Involuntary Movements (Dyskinesia)
Tell patient
Uncontrolled writhing, twitching, or jerking movements may occur, especially at higher doses. This is a sign the dose may need adjustment. Do not reduce or stop the medication on your own.
Call prescriber
If new involuntary movements appear, worsen, or significantly affect daily activities.
Hallucinations & Unusual Behaviour
Tell patient
Some people experience vivid dreams, visual hallucinations, or unusual impulses such as gambling, increased shopping, or compulsive eating. Caregivers should be informed as patients may not recognize these changes.
Call prescriber
If hallucinations occur (seeing or hearing things that are not present), if new compulsive behaviours develop, or if paranoia or delusional thinking is noticed.
Discoloured Body Fluids
Tell patient
Urine, sweat, and saliva may turn a dark red, brown, or black colour. This is a harmless effect of levodopa metabolites and is not a sign of internal bleeding. Light clothing may become stained.
Call prescriber
No action needed for discolouration alone. However, contact the prescriber if you notice blood in urine, stool, or vomit.
Never Stop Suddenly
Tell patient
Abruptly stopping this medication can cause a dangerous condition resembling neuroleptic malignant syndrome, with high fever, severe rigidity, and confusion. Always follow a supervised tapering plan.
Call prescriber
If you run out of medication, if hospitalised staff try to hold your doses, or if you experience rigidity and fever after missing doses. Seek immediate medical attention.
Vitamin B6 Monitoring
Tell patient
This medication can lower vitamin B6 levels over time, which may cause numbness, tingling, depression, or in rare cases seizures. Your doctor may check B6 levels periodically and recommend a supplement.
Call prescriber
If you develop new numbness or tingling in hands or feet, unexplained low mood, or any seizure activity.
Sources
Regulatory (PI / SmPC)
- Sinemet (carbidopa and levodopa) Tablets — FDA Prescribing Information. Revised 2020. accessdata.fda.gov Primary source for dosing, contraindications, warnings, and adverse reaction data for the immediate-release formulation.
- Sinemet CR (carbidopa levodopa) Sustained-Release Tablets — FDA Prescribing Information. Revised 2014. accessdata.fda.gov Source for controlled-release formulation dosing and pharmacokinetic differences versus IR.
- Rytary / Carbidopa and Levodopa ER Capsules — FDA Prescribing Information. drugs.com/pro Source for extended-release capsule dosing, conversion tables, and adverse events in early and advanced PD trials.
- FDA Drug Safety Communication: FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa. March 20, 2026. fda.gov New FDA required warning regarding B6 depletion, seizure risk, and monitoring recommendations; informs the regulatory warning block.
Key Clinical Trials
- Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease: a multicenter 5-year study (CR First Study Group). Eur Neurol. 1997;37(1):23–27. doi:10.1159/000117399 Five-year head-to-head trial of IR vs CR in levodopa-naïve patients; primary source for discontinuation rates and long-term motor fluctuation incidence.
- Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–356. doi:10.1016/S1474-4422(13)70025-5 Pivotal trial for extended-release capsule (Rytary) demonstrating increased “on” time versus IR in advanced PD.
Guidelines
- Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson’s Disease. Mov Disord. 2018;33(8):1248–1266. doi:10.1002/mds.27372 MDS evidence review confirming levodopa as the most effective agent for motor symptoms; basis for first-line status.
- National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults (NG71). Updated July 2017. nice.org.uk UK guideline recommending levodopa as first-line when motor symptoms significantly affect quality of life.
Mechanistic / Basic Science
- Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa. Ann Neurol. 1985;18(5):537–543. doi:10.1002/ana.410180505 Seminal PK study showing carbidopa doubles levodopa bioavailability and halves its plasma clearance; informs the ADME section.
- Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62(6):905–910. doi:10.1001/archneur.62.6.905 Demonstrates that continuous dopaminergic stimulation reduces motor complications versus pulsatile dosing.
Pharmacokinetics / Special Populations
- Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989;28(1):61–69. doi:10.1111/j.1365-2125.1989.tb03506.x Demonstrates increased levodopa AUC (~55%) in elderly subjects; informs dosing caution in older patients.
- Contin M, Riva R, Martinelli P, et al. Pharmacokinetics of levodopa and 3-O-methyldopa in parkinsonian patients treated with levodopa and carbidopa or levodopa alone. Clin Neuropharmacol. 1991;14(6):534–541. PubMed Characterises 3-OMD accumulation during chronic therapy; relevant to COMT inhibitor rationale.
- Stalevo (carbidopa, levodopa and entacapone) Tablets — FDA Prescribing Information. accessdata.fda.gov Source for protein binding values (levodopa 10–30%, carbidopa ~36%) and carbidopa elimination half-life data.